Targeting KRAS in a TRP53/KRAS mouse and organoid model inhibits Barrett Esophagus to Gastroesophageal Adenocarcinoma progression
RNA-seq (gene expression) · mouse · 20 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 20 samples: 7 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE333534_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1471267 and SRA study SRP704262. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 17 samples.
How we read this: 7 replicated groups read from 20 sample titles; they account for 17 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9768072 L2-L_1_batch1 L2-L_1
- GSM9768073 L2-L_2_batch1 L2-L_2
- GSM9768074 L2-L_3_batch1
- GSM9768075 L2-L_1_batch2 L2-L_1
- GSM9768076 L2-L_2_batch2 L2-L_2
- GSM9768077 L2-L_1_batch3 L2-L_1
- GSM9768078 L2-L_2_batch3 L2-L_2
- GSM9768079 L2-LP_1_batch2 L2-LP_1
- GSM9768080 L2-LP_2_batch2 L2-LP_2
- GSM9768081 L2-LP_1_batch3 L2-LP_1
- GSM9768082 L2-LP_2_batch3 L2-LP_2
- GSM9768083 L2-LP_3_batch3
- GSM9768084 L2-LK_1_batch3
- GSM9768085 L2-LKP_1_batch1 L2-LKP_1
- GSM9768086 L2-LKP_2_batch1 L2-LKP_2
- GSM9768087 L2-LKP_2_batch2 L2-LKP_2
- GSM9768088 L2-LKP_3_batch2 L2-LKP_3
- GSM9768089 L2-LKP_1_batch3 L2-LKP_1
- GSM9768090 L2-LKP_2_batch3 L2-LKP_2
- GSM9768091 L2-LKP_3_batch3 L2-LKP_3
- GSE301303 Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo 65 samples shares kras, adenocarcinoma
- GSE253461 Single-cell transcriptional profiling of wildtype Rosa26(YFP) (Y) and Kras(G12D) p53(-/-) Rosa26-YFP (KPY) lung AT2 epithelial cells, AT2 organoids, and co-cultured mesenchymal cells with temporal resolution 39 samples shares kras, organoid
- GSE277392 Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity 31 samples shares kras, adenocarcinoma
- GSE252971 CasRx-Based KRASG12D Silencing for In Vivo Tumor Inhibition in Spontaneous Lung Adenocarcinoma 28 samples shares kras, adenocarcinoma
- GSE301568 Effect of treating AKPS organoids with either single agent KRAS G12C inhibition, TEAD inhibiton or APC restoration, or dual and triple combination on gene expression. 24 samples shares kras, organoid
- GSE301620 Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo [R_invivo_invitro] 23 samples shares kras, adenocarcinoma
- GSE264527 Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with combined SOS1 and MEK Inhibition for Improved Immunotherapy Response 21 samples shares kras, adenocarcinoma
- GSE301301 Targeted KRAS G12V degradation elicits efficient and durable lung adenocarcinoma regression in vivo [dTAG_expt1_RNAseq] 16 samples shares kras, adenocarcinoma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.